FStar Therapeutics Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and FStar Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days FStar Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, FStar Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 18.5 M | |
| Total Cashflows From Investing Activities | -643 K |
FStar |
FStar Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in FStar Therapeutics on November 13, 2025 and sell it today you would earn a total of 100.00 from holding FStar Therapeutics or generate -100.0% return on investment over 90 days. FStar Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than FStar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FStar Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of FStar Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for FStar Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| FStar Therapeutics is not yet fully synchronised with the market data | |
| FStar Therapeutics has some characteristics of a very speculative penny stock | |
| FStar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 21.17 M. Net Loss for the year was (31.28 M) with profit before overhead, payroll, taxes, and interest of 21.17 M. | |
| FStar Therapeutics currently holds about 35.57 M in cash with (27.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.62. |
FStar Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of FStar Stock often depends not only on the future outlook of the current and potential FStar Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. FStar Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 20.6 M | |
| Cash And Short Term Investments | 78.5 M |
FStar Therapeutics Fundamentals Growth
FStar Stock prices reflect investors' perceptions of the future prospects and financial health of FStar Therapeutics, and FStar Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FStar Stock performance.
| Return On Equity | -0.61 | |||
| Return On Asset | -0.22 | |||
| Profit Margin | (2.11) % | |||
| Operating Margin | (1.62) % | |||
| Current Valuation | 98.23 M | |||
| Shares Outstanding | 21.98 M | |||
| Price To Book | 2.13 X | |||
| Price To Sales | 5.47 X | |||
| Revenue | 21.17 M | |||
| EBITDA | (30.17 M) | |||
| Cash And Equivalents | 35.57 M | |||
| Cash Per Share | 1.62 X | |||
| Total Debt | 9.61 M | |||
| Debt To Equity | 0.22 % | |||
| Book Value Per Share | 2.59 X | |||
| Cash Flow From Operations | (27.27 M) | |||
| Earnings Per Share | (1.83) X | |||
| Total Asset | 123.02 M | |||
Things to note about FStar Therapeutics performance evaluation
Checking the ongoing alerts about FStar Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FStar Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FStar Therapeutics is not yet fully synchronised with the market data | |
| FStar Therapeutics has some characteristics of a very speculative penny stock | |
| FStar Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 21.17 M. Net Loss for the year was (31.28 M) with profit before overhead, payroll, taxes, and interest of 21.17 M. | |
| FStar Therapeutics currently holds about 35.57 M in cash with (27.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.62. |
- Analyzing FStar Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FStar Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining FStar Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FStar Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of FStar Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FStar Therapeutics' stock. These opinions can provide insight into FStar Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in FStar Stock
If you are still planning to invest in FStar Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FStar Therapeutics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |